Department of Neurology, University of California, Irvine, 200 S. Manchester Ave., Suite 206E, Orange, CA, 92868, USA.
Departments of Pharmacy, University of California, Irvine, Orange, CA, USA.
Neurocrit Care. 2020 Jun;32(3):707-714. doi: 10.1007/s12028-020-00951-1.
BACKGROUND/OBJECTIVE: Intravenous nicardipine infusion is effective for rapid blood pressure control. However, its use requires hemodynamic monitoring in the intensive care unit (ICU) and is associated with high hospital cost. This study aimed to examine the effect of early versus late initiation of oral antihypertensives on ICU length of stay (LOS) and cost of hospitalization in patients with hypertensive intracerebral hemorrhage (ICH).
This is a single-center retrospective study of patients with hypertensive ICH treated with nicardipine infusion from January 1, 2013, to December 31, 2017. Patients were dichotomized into study and control groups, based on receiving oral antihypertensives within 24 h versus after 24 h of emergency department arrival. Baseline characteristics, duration of nicardipine infusion, LOS in the ICU and hospital, functional outcome at discharge, and hospital cost were compared between the two groups using univariate and multivariate analysis.
A total of 90 patients in the study group and 76 in the control group were identified. There was no significant difference in demographics, past medical history, and initial SBP between the two groups. After adjusting for confounding factors with multivariate regression models, early initiation of oral antihypertensives was associated with significant reductions in duration of nicardipine infusion (55.5 ± 60.1 vs 121.6 ± 141.3 h, p <0.005), nicardipine cost ($14,207 vs $29,299, p < 0.01), ICU LOS (2 vs 5 days, p < 0.005), and cost of hospitalization ($24,564 vs $47,366, p < 0.01). There was no significant difference in adversary renal events, favorable outcomes, and mortality between the two groups.
Early initiation of oral antihypertensives is safe and may have a significant financial impact on patients with hypertensive ICH.
背景/目的:静脉注射尼卡地平输注对于快速控制血压是有效的。然而,其使用需要在重症监护病房(ICU)进行血流动力学监测,并且与高医院成本相关。本研究旨在检查早期与晚期开始口服降压药对高血压性脑出血(ICH)患者 ICU 住院时间(LOS)和住院费用的影响。
这是一项单中心回顾性研究,纳入了 2013 年 1 月 1 日至 2017 年 12 月 31 日期间接受尼卡地平输注治疗的高血压性 ICH 患者。患者根据急诊到达后 24 小时内接受口服降压药与 24 小时后接受口服降压药分为研究组和对照组。使用单变量和多变量分析比较两组之间的基线特征、尼卡地平输注时间、ICU 和医院 LOS、出院时的功能结局和住院费用。
研究组有 90 例患者,对照组有 76 例患者。两组患者的人口统计学特征、既往病史和初始 SBP 无显著差异。在使用多变量回归模型调整混杂因素后,早期开始口服降压药与尼卡地平输注时间显著缩短(55.5 ± 60.1 小时比 121.6 ± 141.3 小时,p < 0.005)、尼卡地平费用($14,207 比 $29,299,p < 0.01)、ICU LOS(2 天比 5 天,p < 0.005)和住院费用($24,564 比 $47,366,p < 0.01)减少有关。两组之间不良肾功能事件、良好结局和死亡率无显著差异。
早期开始口服降压药是安全的,可能对高血压性 ICH 患者产生重大的财务影响。